Accurate label claims are essential for consumer trust in probiotic efficacy, yet limited datasets are available for poultry formulations marketed in the United Kingdom. We quantified and identified the viable bacteria in twelve commercial probiotics, seven for poultry and five for human use, using selective plate counts and MALDI-TOF MS. Observed colony forming units (CFU) were compared with declared values using one-sample t-tests, adopting a practical acceptance range of ±0.5 log CFU. Poultry products largely met or exceeded their labels (e.g., P5: 1.4 × 1010 CFU g−1 vs. 2 × 109 CFU g−1 declared), whereas human products delivered greater variability in both species composition and stated CFU count; one contained no detectable viable bacteria. All products deviated significantly from their label claims (p < 0.05); however, 11 of 12 met the ±0.5 log10 CFU benchmark—10 within the range and 1 above its “≥” value—leaving only one probiotic below the threshold. MALDI-TOF MS confirmed the presence of most labelled species, though Bifidobacterium bifidum was absent from one human product and Bacillus isolates were re-assigned to B. velezensis/B. amyloliquefaciens. These findings indicate robust quality assurance in UK poultry probiotics, but substantial under-delivery in the human probiotics, underscoring the need for harmonized viability standards and tighter post-market surveillance.
Background: Prompt administration of optimal antibiotic therapy is essential in the management of bacteraemia to reduce morbidity and mortality and to facilitate antibiotic stewardship. To identify the most effective therapy, rapid and accurate antimicrobial susceptibility testing (AST) is essential. ASTar is an automated AST system that delivers minimum inhibitory concentrations (MICs) for 23 antimicrobials and is designed for testing Gram-negative bacteria directly from positive blood cultures, with results available after 6 h. Methods: The ASTar system was evaluated with 64 positive blood cultures from patients with bacteraemia and 56 simulated blood cultures inoculated with a range of antibiotic-resistant isolates. The ASTar results for 12 antibiotics commonly used in our hospitals were compared with the results derived from three different methods of disc susceptibility testing and MICs determined by broth microdilution (BMD). Results: For 121 isolates of Gram-negative bacteria, ASTar showed an average essential agreement of 87.2% and an average categorical agreement of 94%, when compared with BMD. Very major errors (false susceptibility) and major errors (false resistance) were associated with 0.9% and 3.4% of results, respectively. The results were at least as accurate as those obtained from EUCAST disc susceptibility methods (both rapid and overnight methods). Conclusions: The ASTar system is an effective method for delivering accurate and rapid (6 h) AST results for Gram-negative bacteria by the direct testing of positive blood cultures.
The aim of this study was to assess the utility of CHROMID® Colistin R for direct detection of colistin-resistant Gram-negative bacteria from positive blood cultures. A total of 390 blood cultures from hospitalised patients containing Gram-negative bacteria were included in this study. These blood cultures were referred to clinical laboratories in the United Kingdom and Türkiye. A further 16 simulated positive blood culture bottles were included that contained a range of colistin-resistant strains as well as susceptible control strains. Fluid from each positive blood culture was diluted 1/200 in saline and 10 µL aliquots cultured onto cystine-lactose-electrolyte-deficient agar and CHROMID® Colistin R. All recovered bacteria were identified, and for Gram-negative bacteria, their minimum inhibitory concentration of colistin was measured using the broth microdilution method. From a total of 443 Gram-negative isolates, 57 colistin-resistant isolates were recovered, of which 53 (93%) grew on CHROMID® Colistin R within 18 h. Of the 377 isolates determined to be colistin-susceptible, only 9 isolates were able to grow, including 6 isolates of Pseudomonas aeruginosa. For positive blood cultures that are shown to contain Gram-negative bacteria, culture on CHROMID® Colistin R is a useful diagnostic tool to detect susceptibility or resistance to colistin within 18 h.